Clinical trial
Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or…
NCT00045526 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00045526 |
|---|---|
| Title | Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer |
| Official title | Phase II Study Of OSI-774 In Advanced Esophageal Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Recurrent Esophageal Cancer, Squamous Cell Carcinoma of the Esophagus, Stage III Esophageal Cancer, Stage IV Esophageal Cancer |
| Intervention type | Drug, Other |
| Interventions | erlotinib hydrochloride, laboratory biomarker analysis |
| Enrollment | 48 |
| Start date | Jun 1, 2002 |
| Primary completion | Feb 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: